草分枝杆菌F.U.36辅治初治肺结核患者的效果及其对免疫功能的影响  

Effect of mycobacteriumphlei F.U.36 in assisting initial treatment of pulmonary tuberculosis and the influence on immune function

作　　者：陆清平 林志强[1] 梁志军[1] 

机构地区：[1]海南省琼海市人民医院感染科,571400

出　　处：《疑难病杂志》2015年第9期929-931,935,共4页Chinese Journal of Difficult and Complicated Cases

摘　　要：目的研究初治肺结核患者应用草分枝杆菌F.U.36辅治的效果及其对免疫功能的影响。方法选择2013年5月—2014年7月收治的肺结核患者86例,按照入院顺序将患者分为观察组(43例)和对照组(43例)。所有患者给予利福平、异烟肼、己胺丁醇等抗结核药物,观察组患者在此基础之上,给予草分枝杆菌F.U.36。观察2组患者治疗后的临床疗效,主要包括症状改善、肺CT改善以及复发情况,观察2组患者治疗前和治疗18周后的免疫功能变化。结果观察组患者的症状总改善率(97.67%)显著高于对照组(83.72%),差异具有统计学意义(x^2=11.900,P<0.01);观察组患者肺部CT病灶总好转率(97.68%)显著高于对照组(81.39%),差异具有统汁学意义(x^2=11.179,P<0.01);治疗后,观察组患者的IgG(8.63±3.76)g/L,IgM(1.13±0.53)g/L,CD_4^+(32.10±13.20)%,CD_8^+(32.30±8.20)%均显著优于对照组的(6.64±3.25)g/L、(0.91±0.47))g/L、(38.60±7.60)%、(27.70±5.60)%,差异均有统计学意义(t=2.626、2.037、2.798、3.038,P<0.05);观察组中无复发患者,对照组出现病情复发8例(18.6%),差异具有统计学意义(x^2=8.821,P<0.05)。结论初治肺结核患者辅以草分枝杆菌F.U.36治疗,能够明显改善患者的症状、病灶和免疫功能,值得广泛推广使用。Objective To investigate the effect and immune function changes of using mycobacterium F ..U.36 in treating patients with pulmonary tuberculosis .Methods From May 2013 to July 2014 , 86 cases of tuberculosis patients were enrolled, the patients were divided according to the order of admission into observation group （43 cases） and control group （43 cases）.All patients were treated with rifampin（0.45 g）, isoniazid（0.3 g）, and amine butanol（0.75 g）,once a day, observation group patients also received mycobacterium F .U.36（1.72 μg/ml）.After treatment’s clinical efficacy, including symptoms , improvement of lung CT and recurrence were observed in all patients , changes in immune function in two groups of patients before treatment and after 18 weeks of treatment were observed .Results The total symptom improvement rate of the observation group （97.67%） was significantly higher than control group （83.72%）, the difference were statistically signifi-cant （χ2 =11.900, P 〈0.01）; after treatment, observation group’s CT lung lesions overall improvement rate （97.68%） was significantly higher than control group （81.39%）, the difference was statistically significant （χ2 =11.179, P 〈0.05）;after treatment, observation group’s IgG （8.63 ±3.76） g /L, IgM （1.13 ±0.53） g /L, CD4＋（32.10 ±13.20）%, CD8＋（32.30 ±8.20）%was significantly better than the control group ’s （6.64 ±3.25） g /L, （0.91 ±0.47）） g /L, （38.60 ±7.60）%, （27.70 ±5.60）%, the difference was statistically significant （ t =2.626, t =2.0375, t =2.798, t =3.038, P 〈0.05）; no recurrence were found in the observation group , and control group had a recurrence of 8 cases （18.6%）, the difference was statistically significant （χ2 =8.821, P 〈0.05）.Conclusion For the initial treatment of tu-berculosis patients , mycobacteriumphlei F .U.36 can significantly improve symptoms , lesions and immune function , it is worth widely used.

关 键 词：肺结核 草分枝杆菌F.U.36 临床效果 免疫功能 

分 类 号：R521[医药卫生—内科学]